Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 17 (2) , 155-161
- https://doi.org/10.1023/a:1006094117427
Abstract
Biological evidence suggests that interference with the function of the angiogenic growth factor receptor VEGFR2 (flk1/KDR) is a particularly promising strategy to inhibit tumor-induced angiogenesis....Keywords
This publication has 0 references indexed in Scilit: